Hikma Pharmaceuticals (LON:HIK – Free Report) had its price target raised by Berenberg Bank from GBX 2,000 ($25.54) to GBX 2,100 ($26.81) in a report published on Monday morning, MarketBeat reports. Berenberg Bank currently has a hold rating on the stock.
HIK has been the subject of several other reports. Barclays reiterated an equal weight rating and issued a GBX 2,000 ($25.54) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, May 7th. Deutsche Bank Aktiengesellschaft reiterated a buy rating and set a GBX 2,750 ($35.11) price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, June 18th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of GBX 2,250 ($28.73).
Read Our Latest Report on Hikma Pharmaceuticals
Hikma Pharmaceuticals Stock Performance
Hikma Pharmaceuticals Cuts Dividend
The firm also recently declared a dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, August 15th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a yield of 1.37%. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is 9,402.99%.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Recommended Stories
- Five stocks we like better than Hikma Pharmaceuticals
- 5 Top Rated Dividend Stocks to Consider
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Compound Interest and Why It Matters When Investing
- Jeff Brown’s Exegesis AI Stock Picks
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.